Artemisinin-derived dimers and their antimalarial activities

Malaria is a tropical disease that leads around half a million people to succumb annually. Antimalarial agents such as artemisinin and its derivatives are crucial to malaria treatment; however, the rapid development of drug resistance to clinically used antimalarials is still the major obstacle to effective chemotherapy. To tackle the growing resistance issue, new antimalarial agents are urgently needed. Using artemisinin-derived dimers as pharmacological scaffolds has demonstrated promising antimalarial activity; therefore, rational design of the dimers may provide valuable therapeutic intervention to treat malaria or even drug-resistant malaria. This review emphasized two aspects: (a) different linker-tethered artemisinin-derived dimers with potential antimalarial activity and (b) the structure-activity relationships discussed to provide an insight for rational design of dimers with improved efficiency.     

Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments

Resistance to chemotherapy is a current clinical problem, especially in the treatment of microbial infections and cancer. One strategy to overcome this is to make new derivatives of existing drugs by conjugation to organometallic fragments, either by an appropriate linker, or by direct coordination of the drug to a metal. We illustrate this with examples of conjugated organometallic metallocene sandwich and half-sandwich complexes, Ru^II and Os^II arene, and Rh^III and Ir^III cyclopentadienyl half-sandwich complexes. Ferrocene conjugates are particularly promising. The ferrocene–chloroquine conjugate ferroquine is in clinical trials for malaria treatment, and a ferrocene-tamoxifen derivative (a ferrocifen) seems likely to enter anticancer trails soon. Several other examples illustrate that organometallic conjugation can restore the activity of drugs to which resistance has developed.     

Recent advances in anticancer ruthenium Schiff base complexes

Nowadays in cancer treatment, both metal complexes and organic molecules are being widely used. Current years have seen a surge of interest in the application of organometallic compounds to treat cancer and other diseases. Undeniably, the unique properties of organometallic compounds, intermediate between those of classical inorganic and organic materials, provide new opportunities in the field of medicinal chemistry. Since the discovery of cisplatin, many transition metal complexes have been synthesized and assayed for anticancer activity. In recent years, ruthenium-based Schiff base complexes have emerged as promising antitumor and antimetastatic agents with potential uses in treatment of platinum-resistant tumors or as alternatives to platinum-based chemotherapy. Advantages of utilizing ruthenium complexes in drug development include reliable methods of synthesizing stable complexes; the ability to tune ligand affinities, electron transfer and substitution rates, and reduction potentials; and an increasing knowledge of the biological effects of such complexes. This great expansion of ruthenium-based Schiff base complexes is mainly due to the unique ability of the ruthenium core to permit multiple oxidation states, hence versatile electron-transfer pathways, and because of the ease of preparation with versatile and variable-denticity Schiff base ligands. This review aims to bring the reader up to date with the more recent Ru(II)/(III)-based Schiff base complexes that have been synthesized and investigated for their cytotoxicity.     

Disulfide-Reductase Inhibitors as Chemotherapeutic Agents: The Design of Drugs for Trypanosomiasis and Malaria

Viewed globally, parasitic diseases such as malaria and Chagas' cardiopathy pose an increasing threat to human health and welfare. Recognition of this problem and the challenge of synthesizing a quinine-like antimalarial agent sparked off the development of the chemical industry about 100 years ago. Our contribution deals with aspects of drug design, a young branch of pharmaceutical chemistry. As drug targets the flavoenzyme, glutathione reductase, and the recently discovered parasite enzyme, trypanothione reductase, were chosen. Based on the knowledge of the structure of these molecules, the modeling of enzyme inhibitors as potential chemotherapeutic agents against parasites has become possible. In addition, biochemical and clinical observations are considered since chemical principles of biological evolution can serve as guidelines for the pharmaceutical chemists. The picture shows two erythrocytes destroyed by malaria parasites. In the center of the photograph a parasite is just leaving its host cell through the ruptured cell membrane. Its target could be a neighboring healthy erythrocyte.     

New antimalarial drugs

Approximately 40% of the world population live in areas with the risk of malaria. Each year, 300-500 million people suffer from acute malaria, and 0.5-2.5 million die from the disease. Although malaria has been widely eradicated in many parts of the world, the global number of cases continues to rise. The most important reason for this alarming situation is the rapid spread of malaria parasites that are resistant to antimalarial drugs, especially chloroquine, which is by far the most frequently used. The development of new antimalarial drugs has been neglected since the 1970s owing to the end colonialism, changes in the areas of military engagement, and the restricted market potential. Only in recent years, in part supported by public funding programs, has interest in the development of antimalarial drugs been renewed. New data available from the recently sequenced genome of the malaria parasite Plasmodium falciparum and the application of methods of modern drug design promise to bring significant development in the fight against this disease.     

Artemisinin and Derivatives-Based Hybrid Compounds: Promising Therapeutics for the Treatment of Cancer and Malaria

Cancer and malaria are major health conditions around the world despite many strategies and therapeutics available for their treatment. The most used strategy for the treatment of these diseases is the administration of therapeutic drugs, which suffer from several shortcomings. Some of the pharmacological limitations associated with these drugs are multi-drug resistance, drug toxicity, poor biocompatibility and bioavailability, and poor water solubility. The currently ongoing preclinical studies have demonstrated that combination therapy is a potent approach that can overcome some of the aforementioned limitations. Artemisinin and its derivatives have been reported to exhibit potent efficacy as anticancer and antimalarial agents. This review reports hybrid compounds containing artemisinin scaffolds and their derivatives with promising therapeutic effects for the treatment of cancer and malaria.     

Synthesis and biological activity of cymantrene and cyrhetrene 4-aminoquinoline conjugates against malaria, leishmaniasis, and trypanosomiasis

Organometallic analogues of chloroquine show promise as new antimalarial agents capable of overcoming resistance to the parent drug chloroquine. Here, the synthesis and characterization of three new cymantrene (CpMn(CO)(3)) and cyrhetrene (CpRe(CO)(3)) 4-aminoquinoline conjugates with either an amine or amide linker are reported. The antimalarial activity of the new organometallic conjugates N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-cymantrenylbutanamide (3), N-(2-(7-chloroquinolin-4-ylamino)ethyl)-4-cyrhetrenylbutanamide (4) and N-(7-chloroquinolin-4-yl)-N'-(cymantrenylmethyl)ethane-1,2-diamine (6) was evaluated against a chloroquine-sensitive (CQS) and a chloroquine-resistant strain (CQR) of the malaria parasite Plasmodium falciparum. The cymantrene complex with an amine linker (6) showed good activity against the CQS strain but was inactive against the CQR strain. In contrast, cymantrene and cyrhetrene compounds with an amide linker were active against both the CQS and the CQR strain. In addition, the antibacterial, anti-trypanosomal and anti-leishmanial activity of the compounds was evaluated. Compound 6 showed submicromolar activity against Trypanosoma brucei at a concentration where the toxicity to normal human cells is low. No significant effect was noticed on the exchange of manganese for rhenium in the CpM(CO)(3) moiety in any of the biological assays.     

金属有机电致磷光材料研究进展

综述了近几年来用于有机发光二极管中的金属有机电致磷光材料的研究进展, 重点评述了重金属铱配合物、稀土元素配合物和含金属配合物的聚合物磷光材料近年来的研究进展, 展望了金属有机配合物电致磷光材料的发展前景.     

Designing organometallic compounds for catalysis and therapy

Bioorganometallic chemistry is a rapidly developing area of research. In recent years organometallic compounds have provided a rich platform for the design of effective catalysts, e.g. for olefin metathesis and transfer hydrogenation. Electronic and steric effects are used to control both the thermodynamics and kinetics of ligand substitution and redox reactions of metal ions, especially Ru(II). Can similar features be incorporated into the design of targeted organometallic drugs? Such complexes offer potential for novel mechanisms of drug action through incorporation of outer-sphere recognition of targets and controlled activation features based on ligand substitution as well as metal- and ligand-based redox processes. We focus here on η(6)-arene, η(5)-cyclopentadienyl sandwich and half-sandwich complexes of Fe(II), Ru(II), Os(II) and Ir(III) with promising activity towards cancer, malaria, and other conditions.     

Synthesis and Antimalarial Activities of New Hybrid Atokel Molecules

The currently spreading resistance of the malaria parasite Plasmodium falciparum to artemisinin-based combination therapies makes an urgent need for new efficient drugs. Aiming to kill artemisinin-resistant Plasmodium, a series of novel hybrid drugs named Atokels were synthesized and characterized. Atokels are based on an 8-amino- or 8-hydroxyquinoline entity covalently bound to a 1,4-naphthoquinone through a polyamine linker. These drugs have been designed to target the parasite mitochondrion by their naphthoquinone moiety reminiscent of the antimalarial drug atovaquone, and to trigger a damaging oxidative stress due to their ability to chelate metal ions in order to generate redox active complexes in situ. The most effective Atokel drug shown a promising antimalarial activity (IC₅₀=622 nm on an artemisinin-resistant P. falciparum strain) and no cytotoxicity at 50 μm indicating a specific antiplasmodial mode of action.     

Parallel synthesis and antimalarial screening of a 4-aminoquinoline library

Due to growing problems with drug resistance, there is an outstanding need for new, cost-effective drugs for the treatment of malaria. The 4-aminoquinolines have provided a number of useful antimalarials, and Plasmodium falciparum, the causative organism for the most deadly form of human malaria, is generally slow to develop resistance to these drugs. Therefore, diverse screening libraries of quinolines continue to be useful for antimalarial drug discovery. We report herein the development of an efficient method for producing libraries of 4-aminoquinolines variant in the side chain portion of the molecule. The effects of these substitutions were evaluated by screening this library for activity against P. falciparum, revealing four potent compounds active against drug-resistant strains.     

Antimalarial Inhibitors Targeting Epigenetics or Mitochondria in Plasmodium falciparum: Recent Survey upon Synthesis and Biological Evaluation of Potential Drugs against Malaria

Despite many efforts, malaria remains among the most problematic infectious diseases worldwide, mainly due to the development of drug resistance by P. falciparum. Over the past decade, new essential pathways have been emerged to fight against malaria. Among them, epigenetic processes and mitochondrial metabolism appear to be important targets. This review will focus on recent evolutions concerning worldwide efforts to conceive, synthesize and evaluate new drug candidates interfering selectively and efficiently with these two targets and pathways. The focus will be on compounds/scaffolds that possess biological/pharmacophoric properties on DNA methyltransferases and HDAC’s for epigenetics, and on cytochrome bc1 and dihydroorotate dehydrogenase for mitochondrion.     

The role of in vitro ADME assays in antimalarial drug discovery and development

The high level of attrition of drugs in clinical development has led pharmaceutical companies to increase the efficiency of their lead identification and development through techniques such as combinatorial chemistry and high-throughput (HTP) screening. Since the major reasons for clinical drug candidate failure other than efficacy are pharmacokinetics and toxicity, attention has been focused on assessing properties such as metabolic stability, drug-drug interactions (DDI), and absorption earlier in the drug discovery process. Animal studies are simply too labor-intensive and expensive to use for evaluating every hit, so it has been necessary to develop and implement higher throughput in vitro ADME screens to manage the large number of compounds of interest. The antimalarial drug development program at the Walter Reed Army Institute of Research, Division of Experimental Therapeutics (WRAIR/ET) has adopted this paradigm in its search for a long-term prophylactic for the prevention of malaria. The overarching goal of this program is to develop new, long half-life, orally bioavailable compounds with potent intrinsic activity against liver- and blood-stage parasites. From the WRAIR HTP antimalarial screen, numerous compounds are regularly identified with potent activity. These hits are now immediately evaluated using a panel of in vitro ADME screens to identify and predict compounds that will meet our specific treatment criteria. In this review, the WRAIR ADME screening program for antimalarial drugs is described as well as how we have implemented it to predict the ADME properties of small molecule for the identification of promising drug candidates.     

The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of action

Despite recent encouraging advances against the disease, malaria remains a major public health problem affecting almost half a billion people and killing almost a million per annum. Due to a short arsenal of efficient antimalarial agents and the frequent appearance of resistance to the drugs in current use, which consequently reduce our means to treat patients, there is a very urgent and continuous need to develop new compounds. This perspective outlines a unique strategy for that purpose through the development of metal-based antimalarial agents. The examples presented here illustrate an attractive alternative to classical drugs.     

Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors

New chemical classes of compounds must be introduced into the malaria drug development pipeline in an effort to develop new chemotherapy options for the fight against malaria. In this review we describe an iterative approach designed to identify potent inhibitors of a kinase family that collectively functions as key regulators of the cell cycle. Cyclin-dependent protein kinases (CDKs) are attractive drug targets in numerous diseases and, most recently, they have become the focus of rational drug design programs for the development of new antimalarial agents. Our approach uses experimental and virtual screening methodologies to identify and refine chemical inhibitors and increase the success rate of discovering potent and selective inhibitors. The active pockets of the plasmodial CDKs are unique in terms of size, shape and amino acid composition compared with those of the mammalian orthologues. These differences exemplified through the use of screening assays, molecular modeling, and crystallography can be exploited for inhibitor design. To date, several classes of compounds including quinolines and oxindoles have been identified as selective inhibitors of the plasmodial CDK7 homologue, Pfmrk. From these initial studies and through the iterative rational drug design process, more potent, selective, and most importantly, chemically unique compound classes have been identified as effective inhibitors of the plasmodial CDKs and the malarial parasite.     

Dynamic stereochemical rearrangements in chiral organometallic complexes

Organometallic complexes have long been known to display a wide variety of dynamic stereochemical processes. Classic examples of such processes include the exchange of axial and equatorial environments in trigonal bipyramidal complexes, such as Fe(CO)(5), and the migration of the metal moiety round the periphery of the cyclopentadiene ring in eta(1)-bound Cp complexes. The systematic study of fluxional processes is of interest because it can not only help provide a detailed, quantitative 'picture' of the bonding between the metals and ligands involved, but it can also help to rationalise chemical reactivity patterns. The introduction of chirality into organometallic complexes, usually in the form of a non-racemic chiral ligand, has led to an explosion in the importance such species, particularly with regard to their applications in organic functional group transformations. The presence of a chiral centre can also provide an excellent spectroscopic handle on the complex in question, enabling both novel fluxional processes to be observed and new light to be shed on old (unresolved) problems. In this critical review (101 references) the literature on metal-centred fluxional rearrangements in chiral transition and main group organometallic complexes is reviewed, complementing the recent review by Faller (see reference 8).     

A personal account of some dinitrogen and organometallic chemistry research at the University of Sussex

This article reviews the development of dinitrogen chemistry and some associated organometallic chemistry at the University of Sussex with which the author was directly involved. The establishment of the basic heavy-element halide phosphine chemistry laid the ground for the discovery of dinitrogen complexes of rhenium, osmium, molybdenum and tungsten. From there, some of the first well-defined reactions of coordinated dinitrogen (especially protonation and alkylation) were discovered and the essential mechanisms of such reactions were established. This allowed the development of models for the action of nitrogenases that are still probably the best available. Later work has produced similar models in iron chemistry and a range of organometallic chemistry has been uncovered in the effort to discover parallels between the basic organometallic chemistry of substances such as metal carbonyls, dinitrogen complexes and hydrides in their interactions with acetylenes and cyclpropene.     

Mechanochemical tools in the synthesis of organometallic compounds

In response to rising environmental concerns, chemistry is experiencing a considerable change in both concepts and practices to adopt more efficient and sustainable technologies. One of the alternative technologies that offer many advantages over the conventional solution-based techniques is mechanochemistry which utilizes mechanical energy to induce chemical reactions. Despite the fact that mechanochemistry has reached high significance in the creation of advanced materials, such as alloys, ceramics, electrode materials, and nanocomposites, in the field of small molecule synthesis its potential remains largely untapped. This review highlights the opportunities and prospects of different mechanochemical tools in the synthesis of organometallic compounds, including transition metal complexes with N-heterocyclic carbene, arene, and cyclopentadienyl ligands, monometallacyclic and pincer derivatives, as well as main group metal compounds (e.g., allyl complexes and the Grignard reagents). Many important organometallic transformations such as C–H bond metalation, transmetalation, and oxidative addition can be successfully implemented under mechanochemical conditions in a highly productive and energy-saving manner. Furthermore, the postmodification of metal-containing species upon grinding or milling is shown to be a powerful route to both new discrete metal complexes and different supramolecular architectures (metal-containing organic cages, macrocylces, networks).     

Methods for the Synthesis of μ-Hydrocarbon Transition Metal Complexes without Metal–Metal Bonds

Transition metal complexes in which hydrocarbons serve as σ,σ-, σ,π- or π,π-bound bridging ligands are currently of great interest. This review presents efficient and directed syntheses for such compounds, which often have very aesthetic structures. These reactions are among the most important reaction types in modern organometallic chemistry. They can be a useful aid for the synthesis of tailor-made compounds, for example, for models of catalytic processes and, specifically, for the construction of heterometallic compounds. We will discuss reactions of electrophilic complexes with nucleophilic ones, numerous transformations of (functionalized) hydrocarbons with metal complexes, the currently very topical complexes with bridging acetylide and carbide ligands, and organometallic polymers, which can be expected to have interesting and novel materials properties. Chisholm

1 M. H. Chisholm, Polyhedron 1988 , 7, 757–1077.

has described the importance of these complexes as follows: “Central to the development of polynuclear and cluster chemistry are bridging ligands and central to organometallic chemistry are metal–carbon bonds. Thus bridging ligands hold a pivotal role ins the development of Binuclear and polynuclear organometallic chemistry”.     

On the medicinal chemistry of ferrocene

Organometallic chemistry and biochemistry have been merged in the last two decades into a new field: bioorganometallic chemistry. This new research area was devoted to the synthesis of new organometallic compounds and their biological and medical effects against some types of diseases, such as cancer and malaria. For several years, the use of ferrocene in bioorganometallic chemistry has been growing rapidly, and several promising applications have been developed since ferrocene is a stable, nontoxic compound and has good redox properties. This review will focus on ferrocenyl compounds which have been biologically evaluated against certain diseases. This area has attracted many researchers due to the promising results of some ferrocene compounds in the medicinal applications. Copyright © 2007 John Wiley & Sons, Ltd.